Johnson & Johnson will pay approximately $5.5 billion (₹52,668 crore) to settle nearly 69,000 lawsuits alleging that its talc products, including baby powder, caused ovarian cancer. The settlement, announced on July 27, aims to resolve about 99.75% of the remaining talc claims consolidated in federal court in New Jersey, as well as related state court cases. The deal represents a significant step towards closing a contentious chapter of litigation that has persisted for over a decade.
Key Details
J&J has consistently denied that its talc products cause cancer, asserting that they are safe and do not contain asbestos. Erik Haas, the company’s Vice President of Litigation, described the claims as "meritless" and stated that the settlement was a strategic decision to achieve closure.
While we are confident the company would have ultimately prevailed with further litigation, this resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,
Haas said.
Background
The company discontinued its talc-based baby powder in the U.S. in 2020, transitioning to a cornstarch alternative. The proposed settlement is subject to approval by the judge overseeing the federal litigation. J&J's legal battles intensified after a California jury ordered the company to pay $966 million to a plaintiff in October, raising questions about the safety of its talc products. The settlement follows a period during which litigation was paused for over three years due to J&J's unsuccessful attempts to resolve the lawsuits through bankruptcy proceedings.
Related coverage: BPCL Reports ₹3,962 Crore Loss; Bharat Coking Coal Declines, Tata Sons FY26 Profit Rises 22% to ₹31,961 Crore, Dividend.
The settlement is likely to affect Johnson & Johnson’s financials, potentially leading to a significant one-time charge against earnings. Investors may also react to the resolution of these legal uncertainties, which have weighed on the company's stock performance. Watch for updates on the court's approval of the settlement and any further legal developments related to the talc litigation.